Nanocarrier systems for delivery of siRNA to ovarian cancer tissues, Expert Opinion on Drug Delivery
Expert opinion:
Gene silencing therapy based on siRNA represents a possible opportunity
for treatment of ovarian cancer patients. However, this approach
requires selection of suitable nanocarriers that can safely and
effectively deliver siRNA to the target site to induce its effect. Very
little work has been done in this field; therefore, it is a good
direction for future development.
